Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trilaciclib in metastatic colorectal cancer (PRESERVE 1)
NCT04607668Phase 3Terminated
- Sponsor
- G1 Therapeutics, Inc.
- Start
- Jan 2021
- Primary completion
- Feb 2023
- Modality
- Small Molecules
- Countries
- 8
01
Overview
A Phase 3 trial of trilaciclib in metastatic colorectal cancer (mCRC), sponsored by G1 Therapeutics, Inc.. Started Jan 2021; status: terminated.
02
Drugs
trilaciclib
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT04607668.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04607668.